As one of the pathological hallmarks in well over 20 neurodegenerative diseases (Lee et al., 2001), tau (tubulin associated unit), gained an increasing interest in the past few years, partly as a result of the large failure rate of clinical trials targeted toward the amyloid hypothesis (Barthel et al., 2015), but also due to recent availability of several tau specific PET ligands (Villemagne et al., 2015). This evidence concerns the gene MAPT and neurodegenerative disease.